Ghana Targets First Locally Manufactured Tetanus-Diphtheria Vaccine by 2027

Ghana is targeting 2027 to begin manufacturing its first locally produced Tetanus-Diphtheria vaccine, as the country steps up efforts to strengthen its pharmaceutical industry and reduce dependence on imported vaccines.

The National Vaccine Institute (NVI) announced the target following the commissioning of new mRNA and protein research laboratories at the Noguchi Memorial Institute for Medical Research in Accra by President John Dramani Mahama on Wednesday.

Chief Executive Officer of the NVI, Dr Sodzi Sodzi-Tettey, said Ghana was working towards producing two vaccine-related products: the Tetanus-Diphtheria vaccine and Anti-Tetanus Serum. The two products were also outlined during the launch of the country’s pharmaceutical manufacturing policy in October.

The vaccines are expected to be developed by two local pharmaceutical companies, Atlantic Lifesciences and DEK Vaccines. However, the companies require at least US$100 million to establish and equip their manufacturing facilities.

The newly commissioned laboratories will serve as national research facilities, providing scientists and researchers from institutions across the country with access to mRNA and protein technology. Ghana is among five African countries currently working with mRNA technology for vaccine research.

The technology allows scientists to develop vaccines by instructing cells to produce specific proteins that trigger an immune response, offering opportunities for faster vaccine development.

President Mahama had earlier allocated US$50 million to the National Vaccine Institute in August 2025 to support the country’s vaccine manufacturing ambitions.

Speaking at the commissioning ceremony, the President called on Ghanaians to support clinical trials, stressing that public participation was essential to the development of locally manufactured vaccines.

“Nobody would do the clinical trials for us to develop vaccines in our country,” he said.

He recalled an earlier attempt to conduct an Ebola vaccine trial in the Volta Region, which was abandoned after public concerns and a scare forced researchers to withdraw from Ghana.

The NVI is now working with the World Health Organisation, with support from the European Union, to strengthen the country’s clinical trials system and build public confidence in vaccine research.

As part of its broader pharmaceutical development agenda, the government has also earmarked US$1 billion for the pharmaceutical sector under its New Economy programme, with plans to establish drug manufacturing and bio-manufacturing hubs.

Ghana currently spends US$46 million on vaccines for child immunisation this year and aims to finance its vaccine needs independently by 2030, when support from Gavi, the Vaccine Alliance, is expected to end.

Meanwhile, five scientists drawn from the Kumasi Centre for Collaborative Research (KCCR), the West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), Noguchi and the University of Health and Allied Sciences have received specialised training in Brussels and Accra to operate the new laboratories. They are expected to transfer their knowledge and skills to other researchers in the country.

The government’s pharmaceutical manufacturing policy also seeks to encourage local production through the use of locally sourced raw materials, research and development, tax exemptions and improved access to financing.

Atlantic Lifesciences has already secured prequalification under the Africa Centres for Disease Control and Prevention’s pooled procurement system and won a contract to supply oxytocin across the continent.

The wider pharmaceutical hub initiative is expected to help reduce Ghana’s reliance on imported medicines, which currently accounts for about 70 per cent of the country’s pharmaceutical needs. The NVI is also in discussions with a European partner on using the laboratory’s mRNA technology for potential cancer vaccine research.

The 2027 vaccine target builds on an earlier milestone achieved in May 2025, when the NVI, in partnership with Atlantic Lifesciences, produced Ghana’s first biological product, a Snake Venom Anti-Serum.

The locally manufactured serum is intended to help address the needs of an estimated 10,000 snakebite victims in Ghana annually, with procurement of the product now underway.

0 0 votes
Article Rating
guest
Optional

0 Comments
Oldest
Newest Most Voted

Posts Tile

0
Would love your thoughts, please comment.x
()
x